- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04543331
Étude observationnelle pour évaluer la résolution et l'efficacité des fluides chez les patients recevant Beovu dans le traitement de la dégénérescence maculaire néovasculaire liée à l'âge (BLUE SKY)
ÉTUDE OBSERVATIONNELLE POUR ÉVALUER LA RÉSOLUTION DES LIQUIDES ET L'EFFICACITÉ CHEZ LES PATIENTS RECEVANT BEOVU (BROLUCIZUMAB) DANS LE CADRE DES TRAITEMENTS CLÉS DANS LA DÉGÉNÉRENCE MACULAIRE NÉOVASULAIRE LIÉE À L'ÂGE
This study was a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
An observational study design, without a strict, mandated visit schedule or mandated treatment regimen was chosen as the most appropriate to collect available data in a real life setting. For that reason, this NIS did not impose a therapy protocol, diagnostic/therapeutic procedure or a visit schedule. The diagnostic or monitoring procedures were only those ordinarily applied to the therapeutic strategy and to routine clinical care and took place as per investigator's discretion. This included e.g. visit frequency, injection frequency and types of assessments performed - only data from routine medical practice was collected as part of the study.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
BLUE SKY consisted of the nAMD-related module BIRL (Brolucizumab In Real Life) and two general, indication-related study modules "BLUE SKY AMD" and "BLUE SKY DME".
Patients were enrolled at 40 centers, which were representatively distributed amongst the 16 German federal states. This should reflect all state-specific health insurance laws and guidelines. Naïve and pre-treated patients were included after decision to start treatment with brolucizumab and consent was given.
All patients were documented either in the AMD or DME-module (Full Analysis Set).
For the BIRL module, only naïve nAMD patients enrolled in 7 selected centers were planned to be documented. All these centers were equipped with the Zeiss PlexElite OCT-A, needed to assess and analyze BIRL specific objectives in a comparable setting. Only images from routine medical practice were collected as part of the study. The study eye was defined as the first eye treated during the study, the other eye was considered as fellow eye. If both eyes were treated at baseline, the eye with the worse VA was chosen as the study eye (if VA was measured equal, the treating ophthalmologist defines the study eye upon his discretion). The prospective observation period per patient was up to 24 months.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Aschersleben, Allemagne, 06449
- Novartis Investigative Site
-
Bayreuth, Allemagne, 95445
- Novartis Investigative Site
-
Berlin, Allemagne, 10713
- Novartis Investigative Site
-
Berlin, Allemagne, 14163
- Novartis Investigative Site
-
Bonn, Allemagne, 53105
- Novartis Investigative Site
-
Breisach, Allemagne, 79206
- Novartis Investigative Site
-
Chemnitz, Allemagne, 09113
- Novartis Investigative Site
-
Cologne, Allemagne, 50968
- Novartis Investigative Site
-
Dresden, Allemagne, 01067
- Novartis Investigative Site
-
Dresden, Allemagne, 01324
- Novartis Investigative Site
-
Esslingen am Neckar, Allemagne, 73728
- Novartis Investigative Site
-
Glauchau, Allemagne, 08371
- Novartis Investigative Site
-
Homburg, Allemagne, 66421
- Novartis Investigative Site
-
Hösbach, Allemagne, 63768
- Novartis Investigative Site
-
Kiel, Allemagne, 24103
- Novartis Investigative Site
-
Leipzig, Allemagne, 04106
- Novartis Investigative Site
-
Magdeburg, Allemagne, 39104
- Novartis Investigative Site
-
Marienberg, Allemagne, 09496
- Novartis Investigative Site
-
Münster, Allemagne, 48145
- Novartis Investigative Site
-
Neubrandenburg, Allemagne, 17036
- Novartis Investigative Site
-
Schönebeck, Allemagne, 39218
- Novartis Investigative Site
-
Stralsund, Allemagne, 18435
- Novartis Investigative Site
-
Sulzbach, Allemagne, 66280
- Novartis Investigative Site
-
Torgau, Allemagne, 04860
- Novartis Investigative Site
-
Waren, Allemagne, 17192
- Novartis Investigative Site
-
Würzburg, Allemagne, 97080
- Novartis Investigative Site
-
-
Bavaria
-
Munich, Bavaria, Allemagne, 81377
- Novartis Investigative Site
-
Neuburg A.d. Donau, Bavaria, Allemagne, 86633
- Novartis Investigative Site
-
Würzburg, Bavaria, Allemagne, 97080
- Novartis Investigative Site
-
Würzburg, Bavaria, Allemagne, 97070
- Novartis Investigative Site
-
-
Hesse
-
Frankfurt am Main, Hesse, Allemagne, 60590
- Novartis Investigative Site
-
-
Lower Saxony
-
Göttingen, Lower Saxony, Allemagne, 37075
- Novartis Investigative Site
-
Osnabrück, Lower Saxony, Allemagne, 49076
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Allemagne, 18057
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Trier, Rhineland-Palatinate, Allemagne, 54296
- Novartis Investigative Site
-
-
Saarland
-
Saarbrücken, Saarland, Allemagne, 66111
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Allemagne, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Allemagne, 04103
- Novartis Investigative Site
-
Schneeberg, Saxony, Allemagne, 08289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Allemagne, 06118
- Novartis Investigative Site
-
-
Thuringia
-
Jena, Thuringia, Allemagne, 07740
- Novartis Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients being treated for nAMD or DME with brolucizumab were enrolled in the study upon signing an informed consent.
La description
Inclusion Criteria:
The unit of analysis was patient-eye, i.e. all criteria were applied to the study eye, unless otherwise specified. Patients were included in the study if they fulfilled the following requisites:
- Diagnosis of nAMD or visual impairment due to DME
- Male and Female nAMD and DME patients with ≥18 years of age at index
- Decision to treat with brolucizumab at baseline visit
- Signed written informed consent
- Patients for whom a therapy with brolucizumab was medically indicated
- Intraretinal and/or subretinal fluid affecting the central subfield of the study eye at Screening
Exclusion Criteria:
- Patients with any contraindication or who were not eligible for treatment with brolucizumab as according to the SmPC
- Patients treated for RVO or CNV other than nAMD
- Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date
- Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis >50% of the total lesion (nAMD)
- Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date
- Patients who have been on anti-VEGF treatment for longer than 3 years (before index date)
- Any medical or psychological condition in the treating physician's opinion which may have prevented the patient from the 24 months study participation
- Patients participating in parallel in an interventional clinical trial
- Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug
- Laser photocoagulation (focal/grid or panretinal) in the study eye during the 3-month period prior to baseline
- Prior use of intraocular or periocular corticosteroids in the study eye provided at least 4 months prior to baseline
- Pregnancy and breast-feeding
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
treatment naïve patients
Patients being the first time treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
|
pre-treated patients
Patients already being treated for nAMD or DME |
There was no treatment allocation. Patients administered Brolucizumab by prescription that had started before inclusion of the patient into the study were enrolled. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of patients' eyes that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF)
Délai: Month 12
|
This outcome measure is part of the BLUE SKY AMD module. This primary study objective was addressed considering treatment naïve and pre-treated patient eyes, analyzed as two independent groups (naïve and switch). |
Month 12
|
|
Mean change in visual acuity (VA) under clinic specific routine treatment schemes
Délai: Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Morphological CNV-Changes under clinic specific routine treatment schemes
Délai: Baseline, month 12
|
This outcome measure is part of the BIRL module. This primary study objective was addressed considering treatment naïve patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eye. |
Baseline, month 12
|
|
Percent of patients maintained on q12w dosing after loading through Week 52
Délai: After loading, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering treatment naïve patient eyes included in the study. |
After loading, month 12
|
|
Change in interval length from last interval before switch (baseline) to last interval at end of follow-up (12 months)
Délai: Baseline, month 12
|
This outcome measure is part of the BLUE SKY DME module. This primary study objective was addressed considering pre-treated patient eyes. Index date (Baseline): defined as the date of the first anti-VEGF injection (brolucizumab) in patient eyes. |
Baseline, month 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Characterize nAMD patients who initiated treatment with brolucizumab with the respect to baseline characteristics
Délai: Baseline
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline
|
|
Evaluate anatomical parameters during treatment with brolucizumab
Délai: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
|
Evaluate VA change from baseline during treatment with brolucizumab
Délai: Baseline, month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Baseline, month 24
|
|
Estimate number of anti-VEGF injections, visits and injection intervals
Délai: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate percentage of switchers during first 6 months and characterize switchers
Délai: Baseline, month 6
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 6
|
|
Estimate discontinuation rate and time to discontinuation
Délai: Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess retreatment criteria
Délai: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the number of OCT
Délai: Month 1-12 and 13-24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Assess the safety of brolucizumab
Délai: Up to month 24
|
nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate anatomical effectiveness
Délai: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate treatment intervals
Délai: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Describe implementation of treatment schemes into clinical practice
Délai: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Evaluate morphological changes under brolucizumab treatment using multimodal imaging
Délai: Up to month 24
|
naive nAMD patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Percentage of patient's eyes with absence of IRF and/or SRF at month 12 (naive and switch)
Délai: Month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 12
|
|
Evaluate anatomical parameters during treatment with brolucizumab
Délai: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Characterize VA change from baseline during treatment with brolucizumab
Délai: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate discontinuation rate during first year of brolucizumab treatment
Délai: Baseline, month 12
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Baseline, month 12
|
|
Estimate time to discontinuation (persistence)
Délai: Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Up to month 24
|
|
Estimate the treatment burden
Délai: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan |
Month 1-12 and 13-24
|
|
Estimate the number of OCT and the number of visits with/without OCT
Délai: Month 1-12 and 13-24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Month 1-12 and 13-24
|
|
Assess safety of brolucizumab
Délai: Up to month 24
|
DME patients. Detailed Outcome Measure as defined in the Statistical Analysis Plan. |
Up to month 24
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CRTH258ADE02
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .